News

Novo Brings Oral Obesity Drug To UAE Patients

European stock markets closed lower Wednesday as the Stoxx Europe 600 fell 0.7%, Germany's DAX 40 sh

A launch in the United Arab Emirates comes as Novo works to recover ground in the weight loss drug market against rival Eli Lilly

Wells Fargo’s chief agriculture economist Dr. Michael Swanson told Bloomberg Businessweek on May 29 that GLP-1 weight-loss drugs (Ozempic, Wegovy, Mounjaro, Zepbound) will eventually match statins at roughly 90 million prescriptions, calling the trend “here to stay” because it’s prescribed, not faddish. So this is the next 90-million-customer industry, sitting in plain sight while everyone ... 5 Stocks Set to Cash in on The Next 90-Million Customer Industry. (It’s Not AI)

The pharmaceutical company's most promising drug candidate has some potential advantages over its rivals.

Novo Nordisk (NYSE:NVO) has introduced the tablet form of its blockbuster obesity treatment Wegovy in the United Arab Emirates, marking the second country worldwide to receive the oral version of the medication. The launch follows regulatory approval granted earlier this week by health authorities in the UAE and comes several months after the Danish pharmaceutical group debuted the product in the United States.

Novo Nordisk (CPSE:NOVO B) has launched the Wegovy pill in the UAE, the first country outside the U.S. to offer this oral obesity treatment. Regulators in the EU have issued positive opinions recommending approval of both the Wegovy pill and a higher dose injectable formulation. The company is expanding obesity care access through partnerships, including a collaboration with NOVI Health in Singapore. Novo Nordisk, through CPSE:NOVO B, is a major player in obesity and diabetes care, and...

The UAE launch marks the start of Novo's global rollout, with additional launches planned later this year.

Eli Lilly and Company just secured a big win as it looks to expand GLP-1 access, mending its partnership with top pharmacy benefit manager CVS Health.

An upcoming trial result could change how investors think about the weight-loss drug market.

We recently compiled a list of the 11 Most Undervalued Pharma Stocks to Invest In. Novo Nordisk A/S (NYSE:NVO) is one of the most undervalued stocks to invest in. TheFly reported on May 27 that NVO announced that it will present new clinical findings from its cardiometabolic portfolio at the 2026 Scientific Sessions of the American […]

PFE targets a catalyst-rich 2026 with pivotal obesity and oncology studies, key data readouts, and regulatory decisions across its pipeline.

Lilly shares soared more than 18% in May.

These 5 long-term growth stocks could benefit from AI, cybersecurity, GLP-1 drugs, and fintech trends over the next decade

Eli Lilly is working on a new GLP-1 drug, and early results suggest it could be a big winner.

CVS Caremark has granted preferred formulary status to both Novo Nordisk's Wegovy and Eli Lilly's Zepbound and Foundayo. This decision reverses Wegovy's prior commercial advantage within CVS Caremark's GLP-1 obesity drug coverage. The change affects access and competitive positioning for GLP-1 obesity therapies in CVS Caremark's network. Novo Nordisk, listed as CPSE:NOVO B, is a key player in GLP-1 based therapies, with Wegovy at the center of its obesity drug portfolio. CVS Caremark's move...

Lilly has split its stock in the past.

We just covered the Claude Stock Portfolio: Top 10 Stocks to Buy According to AI Chatbot. Eli Lilly and Company (NYSE:LLY) ranks #2 (see Claude Stock Portfolio: Top 5 Stocks to Buy According to AI Chatbot). Number of Hedge Funds: 137 Eli Lilly and Company (NYSE:LLY) is among the top stock picks of the Claude […]

Eli Lilly hits a record high after CVS expands coverage for Foundayo and Zepbound, boosting obesity drug access and raising the stakes in its rivalry with NVO.

CVS restores broader Zepbound coverage after price cuts, putting Wegovy and Zepbound on equal footing.

Eli Lilly's $1 trillion comeback is powered by the company's experimental next-generation obesity drug, Reta.

The change could improve patient access and support future sales growth.

The move gives patients broader access to Lilly's obesity drugs and strengthens competition with Novo Nordisk.

Eli Lilly shares are on pace to hit a new all-time closing high on news of increased insurance coverage for its blockbuster weight-loss drug Zepbound. Lilly shares were recently up 4.4% to $1,130.90. Pharmacy-benefit manager CVS Caremark decided to add back Lilly’s Zepbound weight-loss drug to its lists of preferred drugs.

CVS Health will reinstate coverage of Eli Lilly's weight-loss injectable Zepbound and begin coverage of the anti-obesity pill Foundayo.

CVS Health’s Caremark will resume insurance coverage of Eli Lilly’s Zepbound and separately begin covering its Foundayo weight-loss pill.

Novo Nordisk lost its lead in the GLP-1 race, but Eli Lilly's valuation is a bit rich.

Hims & Hers is acquiring Australian telehealth platform Eucalyptus as part of its international expansion plan while using $350 million in convertible senior notes.

Novo Nordisk's (NYSE:NVO) investor relations team presented at Deutsche Bank's European Champions Conference, with the broker maintaining its hold rating and DKK290 target price on the Danish pharma group. The key takeaway concerned the launch of Novo's oral semaglutide product, where the...

Small biotech firms "latch onto" AI more quickly than bigger firms, the head of ‌Chinese tech giant Tencent's healthcare division said on ‌Thursday, as more businesses embrace AI to improve efficiency. Pharmaceutical companies are also increasingly ​turning to AI to accelerate research and development, betting on new modeling tools and automated labs to improve efficiency and slash costs as well as drug development timelines. Drugmakers including Novo Nordisk ‌and Eli Lilly have ⁠announced AI-related collaborations with technology firms.